November 2022 - Page 3 of 4 - BioMedWire (BMW)

TuesdayNov 15, 2022 2:35 pm

Researchers Turn to AI for Insights on Treating Brain Tumors

With the fields of machine learning and artificial intelligence (AI) evolving almost daily, experts in several industries are trying to figure out ways the technology can advance their specific sectors. Artificial intelligence can analyze an unfathomable number of data points in shockingly little time and come up with conclusions that would have otherwise taken hundreds if not thousands of human work hours. In medicine, researchers hope this ability can help them treat two of the most difficult-to-treat diseases on the planet: brain and spinal tumors. Referred to as cavernous malformations, these are vascular tumors that develop in the spinal cord…

MondayNov 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of…

MondayNov 14, 2022 10:29 am

Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence

Even though there are several treatments that can be used to fight cancer and prolong a cancer patient’s life, the disease has no cure. For the longest time, scientists have been trying to find treatments that could completely eradicate cancer cells without the side effects typically associated with conventional cancer treatments, but no success has been registered. Recent research from the University of Basel has revealed that abnormal cancer cells specifically use sugar molecules on their surface to defend themselves against the immune system. According to University of Basel researchers, this mechanism can nullify this mechanism and make cancer cells…

MondayNov 14, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete Response With GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the disease CNS’ management is optimistic about its lead drug candidate and continues to explore the potential…

FridayNov 11, 2022 1:22 pm

Genes That Saved People from Bubonic Plague Linked to Autoimmune Conditions Today

More than 700 years ago, a pandemic called the Black Death tore across Europe, taking an estimated 75 million to 200 million lives and reducing the continent’s population by around 30% to 60%. The Black Death was the first wave of a pandemic that lasted almost 500 years and is said to be the largest-ever catastrophe involving infectious diseases. Centuries later, the genetic traits that enabled people to fight off the bubonic plague are associated with an increased risk of certain autoimmune disorders. Researchers studying DNA from survivors and victims of the bubonic plague found that people who had a…

ThursdayNov 10, 2022 10:15 am

Research Finds New Therapy Path for Brain Cancer

Brain cancer affects hundreds of thousands of people globally every year and, together with central nervous system tumors, is estimated to take more than 200,000 lives. Research has also found that brain tumors make up 85% to 90% of all central nervous system tumors. Physicians usually treat brain cancer with radiation therapy, chemotherapy and surgery. However, brain tumors often recur after treatment and, in some cases, cannot be removed from the brain. As such, researchers are always looking for a more effective brain cancer treatment that can treat tumors and keep them away for the long term. A recent discovery…

ThursdayNov 10, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patients GBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapy The company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global study CNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million CNS Pharmaceuticals (NASDAQ: CNSP), an…

WednesdayNov 09, 2022 11:28 am

Study Finds Iron Causes Chronic Heart Failure in Heart Attack Survivors

Chronic heart failure is known to develop over time, with experts finding that the primary causes of heart failure include coronary artery disease, myocardial infarction and high blood pressure. Now, new research has found that iron promotes fatty tissue formation within the heart, causing chronic heart failure among roughly 50% of heart attack survivors. This study was carried out by researchers at the School of Medicine inIndiana University, led by Dr. Rohan Dharmakumar. Dharmakumar is the associate director in charge of research at the IU Cardiovascular Institute, which is a joint venture between IU Health and IU School of Medicine.…

WednesdayNov 09, 2022 9:45 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Poised to Potentially Reduce Long-Term Risks Associated with Concussion

Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of administration Through its drug candidate, Odyssey hopes to reduce the risks and potential for long-term consequences associated with concussions Up until Olympic gold medalist Katie Weatherston was forced into retirement following a series of…

TuesdayNov 08, 2022 1:20 pm

New Discovery May Improve Prospects for Patients with Cancer

CDC data shows that cancer death rates have been dropping for the last two decades, with a decline of 27% being recorded in the period between 2001–2020. Researchers believe that this can be attributed to improvements in current cancer treatment and diagnostic procedures as well as the use of precise gene sequencing approaches to help treat cancer. Despite this, many individuals still succumb to this fatal illness, with some cancers heightening the risk of a patient dying. For instance, colorectal, pancreatic and lung cancers make up about 40% of all cancer deaths recorded in America. In an effort to improve…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: November 2022

Researchers Turn to AI for Insights on Treating Brain Tumors

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

Genes That Saved People from Bubonic Plague Linked to Autoimmune Conditions Today

Research Finds New Therapy Path for Brain Cancer

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

Study Finds Iron Causes Chronic Heart Failure in Heart Attack Survivors

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Poised to Potentially Reduce Long-Term Risks Associated with Concussion

New Discovery May Improve Prospects for Patients with Cancer

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search